Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 11,302,800 | 8,768,000 | 9,353,402 | 9,498,600 | 8,312,100 |
| Cost of Goods | 2,170,200 | 1,673,500 | 1,788,000 | 1,860,100 | 1,807,400 |
| Gross Profit | 9,132,600 | 7,094,500 | 7,565,400 | 7,638,500 | 6,504,700 |
| Operating Expenses | 4,983,000 | 4,586,000 | 5,177,600 | 7,188,200 | 4,379,400 |
| Operating Income | 4,149,800 | 2,509,000 | 2,387,801 | 450,399 | 2,125,700 |
| Other Income | -632,600 | 27,100 | 120,999 | -23,199 | -36,800 |
| Pre-tax Income | 3,517,200 | 2,536,100 | 2,508,800 | 427,200 | 2,088,900 |
| Income Tax | 550,200 | 293,200 | 319,100 | 484,600 | 325,700 |
| Net Income Continuous | 2,967,000 | 2,242,900 | 2,189,700 | -57,400 | 1,763,200 |
| Net Income | $2,967,000 | $2,242,900 | $2,189,700 | $-57,400 | $1,763,200 |
| EPS Basic Total Ops | 3.29 | 2.49 | 2.43 | -0.06 | 1.96 |
| EPS Basic Continuous Ops | 3.29 | 2.49 | 2.43 | -0.06 | 1.96 |
| EPS Diluted Total Ops | 3.28 | 2.48 | 2.42 | -0.06 | 1.95 |
| EPS Diluted Continuous Ops | 3.28 | 2.48 | 2.42 | -0.06 | 1.95 |
| EPS Diluted Before Non-Recurring Items | 3.92 | 2.58 | 2.49 | 0.10 | 2.11 |
| EBITDA(a) | $4,564,200 | $2,909,600 | $2,775,503 | $861,399 | $2,492,000 |